ALS ONE's 5th Annual ALS ONE Research Symposium, held Oct. 6, 7, & 11, 2022, hosted by our research team: Dr’s Merit Cudkowicz, MD, MSc of MGH, Robert Brown, MD, DPhil of UMass Medical School, James Berry, MD, MPH of MGH, Sabrina Paganoni, MD, PhD of MGH, and Fernando Vieira, MD of ALS TDI. The conference had over 960 registered guests from 34 countries, including researchers, scientists, and members of the ALS community from around the world, convening virtually for 3 days of sharing critical research that is underway across the globe to help uncover therapeutic options leading to an ultimate cure for Amyotrophic Lateral Sclerosis (ALS). Recordings were made of the presentations which we are/were approved to share.

IN THIS VIDEO:

Symposium Segment: Industry Presentations

Presentation Title: Rationale and design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers: The ATLAS Study.

Speaker: Michael Benatar, MBChB, MS, DPhil, Walter Bradley Chair in ALS Research; Professor of Neurology; Chief, Neuromuscular Division; Executive Director of The ALS Center; Vice Chair, Clinical & Translational Research Department of Neurology, Miller School of Medicine at the University of Miami.

Moderator: Robert H. Brown, Jr., MD, DPhil, Professor and Chair of Neurology at the University of Massachusetts Medical School. Director of the Day Neuromuscular Research Laboratory at the University of Mass. Medical School.

ALS ONE is a 501c3 non-profit organization focused entirely on ALS research and care. To learn more about ALS ONE and/or support our mission, visit: www.alsone.org.

свернуть